Application Value Of Combined Whole Body Bone Scintigraphy And Serum CA15-3,CEA In Breast Cancer With Bone Metastases

Objective To explore the diagnostic value and efficiency evaluation of combined whole body bone scintigraphy and the CA15-3,CEA level in breast cancer patients with bone metastases.Methods 90 cases confirmed by pathology or cytology of breast cancer patients from steptember 2013 to July 2015 were involved in this retrospective analysis.The reasults of whole body bone scintigraphy and CA15-3, CEA test results were analyzed; The differences of serum CA15-3,CEA concentrations between breast cancer patients bone scintigraphy positive and negative groups were analyzed by Student’s t test; The whole body bone scintigraphy result of breast cancer patients were classific by Soloway classification criterion,which were divided into 4 grades, MO respectively:haven’t seen the whole body bone scintigraphy abnormalities; M1:1～22 bone metastases; M2:bone metastases 3-5; M3:bone metastases is greater than 5. The correlations between the whole bone scintigraphy classification and the CA15-3, CEA level were analyzed with Spearman correlation analysis. Before and after treatment 34 patients with bone metastases were selected and analysis of the whole body bone scintigraphy and the change of CA15-3 and CEA levels.Results 56 patients were found in 90 cases of patients with breast cancer with bone metastases and the bone metastasis rate was 62.22%(56/90). The sensitivity, specificity and accuracy of whole body bone scintigraphy were 89.26%(50/56),76.47%(26/34),85.56%(77/90), respectively. The CA15-3,CEA level in the bone metastases patients were statistically higher in the group with the whole body bone scintigraphy positive than those in the group with whole body bone scintigraphy negitive (P< 0.05). In 56 patients with bone metastases, a total of 12 cases of M1, accounted for 21.42%(12/56), M2, a total of 20 patients,35.72%(20/56), M3, a total of 24 cases,42.85%(24/56), M1, M2, and M3 each CA15-3 and CEA levels was rise. The whole body bone scintigraphy classification were positively correlated with CA15-3,CEA levels (r s= 0.727,0.703,).After treatment,the whole body bone scintigraphy classification and the level of CA15-3,CEA were decreased in patients with bone metastases(all P<0.05).Conclusion The whole body bone scintigraphy shows high clinical diagnostic performance in the diagnosis of breast cancer with bone metastases, can be used as screening diagnosis of bone metastases of breast cancer, which has important clinical application. Whole body bone scintigraphy combined CA15-3 and CEA detection help to improve breast cancer bone metastases detection rate, clinical practicability.Follow-up treatment in the process of the whole body bone scintigraphy and dynamic monitoring of CA15-3 and CEA levels helps to evaluate curative effect.